{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-002126","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.922673+00:00","generated_at":"2026-06-20T12:55:43.366579+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst Biosciences terminates CSO Grant Blouse effective Jan 15, 2023","bullets":["Grant Blouse terminated as Chief Scientific Officer effective January 15, 2023.","Severance per employment agreement plus bonus payments previously disclosed in Dec 27, 2022 8-K.","Blouse will provide consulting services regarding potential sale or license of legacy hemophilia programs.","Company retains Blouse's expertise while reducing executive headcount."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-002126","json":"https://secwatch.observer/filing/0001140361-23-002126.json","markdown":"https://secwatch.observer/filing/0001140361-23-002126.md","text":"https://secwatch.observer/filing/0001140361-23-002126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/0001140361-23-002126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/brhc10046770_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T12:55:43.366579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d631ce9f42","claim":"Grant Blouse was terminated as Chief Scientific Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 15, 2023, Catalyst Biosciences, Inc. (the “Company’”) terminated Grant Blouse Ph.D. from his position as the Chief Scientific Officer of the Company, effective as of January 15, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123002126/0001140361-23-002126-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}